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The International Association for the Study of Lung Cancer (IASLC) Strategic Screening Advisory Committee 
(SSAC) has prepared the following response to the United 
States Preventive Services Task Force (USPSTF) draft recom-
mendation on computed tomography (CT) screening [http://
www.uspreventiveservicestaskforce.org/uspstf13/lungcan/
lungcandraftrec.htm] with the associated systemic review.1 
The Cancer Care Ontario Programme in Evidence-Based 
Care (CCOP)2 has also undertaken a similar systemic review. 
The IASLC SSAC was set up during the World Lung Cancer 
Conference 2011.3
Lung cancer remains the most lethal cancer across the 
world. Almost 90% of those cancers are thought to be the 
consequence of prolonged exposure to tobacco-combustion 
products. The USPSTF recent draft recommendations of the 
statement on lung cancer screening, recommended the use 
of low-dose CT (LDCT) screening in certain populations of 
current and former smokers, which were otherwise healthy, 
as a cancer-screening approach. This recommendation was 
buttressed by a large body of information, but most signifi-
cant was the large, randomized National Lung Screening Trial 
(NLST),4 which reported a reduction in tobacco-related lung 
cancer mortality of 20% after 6 years of follow-up after a 
baseline and two annual follow-up rounds of CT screening.
IMPLICATIONS OF THE IMPLEMENTATION OF 
CT SCREENING IN THE UNITED STATES
The USPSTF draft recommendation is a welcome endorse-
ment of LDCT screening to combat a devastating disease. The 
recommendation considered the effectiveness of CT screening in 
reducing mortality, the performance characteristics of CT screen-
ing, the effectiveness of surgical resection in early-stage disease, 
and the harms of both screening and surgical resection. However, 
these recommendations go beyond a restatement of reduced lung 
cancer mortality in high-risk individuals; they challenge the U.S. 
health care system to continue to improve the CT screening pro-
cess as implementation begins. Several unanswered questions 
that will determine the ultimate success of implementation are 
proffered. These include the appropriate risk groups to consider, 
the effects of screening in different demographic subgroups, 
cost effectiveness, the modeling of radiation effects, methods 
to improve the discrimination between benign and malignant 
nodules, the incorporation of biological markers, the integration 
of intensive tobacco cessation for persistent users, and the psy-
chological consequences of screening on health behaviors and in 
clinical practice. The Task Force encourages screening in high-
risk individuals while concurrently appealing to the medical 
work force to better delineate the benefits to risks of lung cancer 
screening. This will require that U.S. screening centers commit to 
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collecting the necessary demographic, clinical, imaging, tobacco 
cessation, and outcomes data to inform these unanswered ques-
tions in the process of screening implementation.
IASLC Statement
The IASLC has previously supported research into CT 
screening trials in the light of the public health burden of lung 
cancer. Each national health service now has an opportunity to 
decide its own way forward regarding the merits of CT screen-
ing based on their interpretation of the existing NLST data and 
information from other lung cancer screening trials. However, 
the IASLC makes the following statements: First, the imple-
mentation of any screening process should be performed incor-
porating best practice for screening care in centers that are able 
to achieve excellence in providing this service and that have a 
multidisciplinary group of experts focused on this problem. In 
discussions about screening, for those who have not done so, 
smoking cessation is the most important measure available to 
improving overall health outcomes. For former smokers con-
sidering lung cancer screening, it is clear that the increased risk 
of developing lung cancer is diminishing but lifelong.5
The IASLC SSAC recommends that the following cur-
rent issues should be considered by national health service pro-
viders as they consider implementing lung cancer screening:
Cost Effectiveness
The cost of providing lung cancer screening is related to the 
process of screening delivery. Preliminary modeling studies in 
the United States have shown that providing lung cancer screen-
ing according to best available practice could be delivered cost 
effectively.6 Valid cost-effectiveness data will ultimately drive the 
success of implementation in many countries, balancing the incre-
mental toll that lung cancer screening will exact on health care 
systems with improved health outcomes. We await cost effective-
ness data from the NLST and Nederlands-Leuvens Longkanker 
Screenings Onderzoek (NELSON) trial data. Moreover, the cost 
effectiveness of lung cancer screening can be further improved by 
the addition of smoking cessation counseling.7
Radiological Protocol for CT Screened Nodules
Size quantification on serial CT scans for lung cancer 
screening is helpful in evaluating whether a pulmonary nodule 
is benign or malignant. Evaluation of suspicious lung nodules 
involving the use of quantitative CT imaging, which allows dis-
crimination of rapidly growing nodules that may be cancer from 
slower growing nodules that are not likely to evolve into cancer, is 
a developing field and the way forward. Many investigators have 
suggested that quantifying whole nodule volume could solve 
some of the limitations of diameter measures8,9 and many studies 
have explored the value of volumetry.10–13 The rigorous applica-
tions of volume measurement guidelines will most likely lead to 
more accurate management of the lung cancer screening process.
Selection Criteria for CT Lung Cancer 
Screening Programs in the United States
The NLST eligibility criteria were based largely on age 
(55–74 years) and heavy-smoking history (≥30 pack-years) 
among current and former smokers (<15 years since quit-
ting). However, as indicated in the USPSTF document, future 
research should include identifying methods for focusing 
LDCT screening on persons at higher risk for disease, to 
improve test sensitivity, specificity, and cost-effectiveness. 
Several risk-prediction models have recently been described to 
better define the optimal risk cohort,14–17 including the model 
developed using the Prostate, Lung, Colorectal and Ovarian 
Cancer Screening Trial data.15 This model improved the sensi-
tivity of LDCT relative to the NLST selection criteria (83.0% 
versus 71.1%, p<0.001) and its positive predictive value (4.0% 
versus 3.4%, p=0.01) without loss of specificity or decrease in 
mortality reduction. Furthermore, a more recent analysis of the 
NLST data reported that the prevention of lung cancer deaths 
in the LDCT screening arm as compared with that in the radi-
ography arm increased according to risk quintiles, with 60% of 
participants at the highest-risk quintiles 3 to 5 accounting for 
88% of the screen-prevented lung cancer deaths, whereas 20% 
of participants at lowest-risk quintile 1, accounting for only 1% 
of lung cancer deaths.18 These results suggest that the appli-
cation of risk-prediction models could reduce the number of 
individuals that need to be screened to prevent one lung cancer 
death, reduce false-positive rates of screening, and improve the 
overall cost-effectiveness of lung cancer screening.
Fitness Criteria and Upper Age Limit
The imposition of any arbitrary upper age limit in select-
ing patients for inclusion in a LDCT screening program is cer-
tain to be challenged by patients and their advocacy groups. 
The use of age is a discredited and inaccurate surrogate for an 
assessment of “fitness” or comorbidity. In addition, any upper 
age limit, such as that of 79 years proposed by the USPSTF, 
will be revised as we better define the demography of the most 
appropriate screening cohorts (http://www.uspreventiveser-
vicestaskforce.org/uspstf13/lungcan/lungcandraftrec.htm).
However, it is reasonable to assess fitness before entry to 
a screening program and at key intervals thereafter to ensure 
that (1) screenees are able to undergo, with tolerable risks, both 
the investigations indicated to evaluate suspicious nodules and 
the subsequent treatment of suspicious nodules or proven lung 
cancers, and (2) their life expectancy because of comorbid 
disease(s) will not prematurely limit their life expectancy rela-
tive to the treatment of a documented lung cancer.
Lung Cancer CT Screening—Considerations  
of Benefits and Harms
The NLST has shown clearly that LDCT benefits patients 
by reducing lung cancer mortality and that this also reduces 
all-cause mortality. Harms may result from physical and psy-
chological sources in the context of discovery of nodules, their 
workup, and overdiagnosis. The latter is especially important, 
as all these harms that apply to life-limiting cancer apply to 
overdiagnosed cancer with none of the benefits, except smok-
ing cessation. It is important to take into account the influence 
of comorbid conditions as NLST showed that individuals with 
multiple comorbid conditions did not benefit from CT screen-
ing.18 This effect can be reduced through careful fitness assess-
ment as outlined above. Harms can also be reduced by the 
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method of workup of nodules. NELSON has shown that the 
frequency of invasive procedures can be minimized by a pro-
tocol to assess growth using CT volumetry at 3- and 12-month 
intervals depending on the size of the nodule detected.19
With modern radiological techniques, radiation dose is 
low, and likely to be even lower in the future. However, it is 
important to ensure adherence to low-dose protocols by ensur-
ing that those managing screening programs are well versed 
in contemporary CT dose-reduction techniques as well as the 
selective use of further diagnostic imaging.
CCOP Guidelines on Lung Cancer Screening
The CCOP have also undertaken an in-depth system of 
review of the screening trials and formulated their guidelines.2 
In essence, many similarities with the USPSTF, except they 
have remained with the NLST selection criteria based on smok-
ing history and age 55 to 74 years. The working group endorsed 
the NLST criteria, however, it did emphasize that patient accept-
ability, cost effectiveness, feasibility, and systems capacity 
would in time indicate whether these parameters were reason-
able. The group also recommended that high-risk individuals 
should be screened for 2 consecutive years and then once every 
2 years after a negative scan, based on evidence from the Multi-
centric Italian Lung Detection Trial (MILD) trial, which did not 
demonstrate a shift to higher-stage disease with biennial screen-
ing compared with annual screening.20 They make a particular 
point that opportunistic screening should not take place and that 
screening should only be undertaken in centers of excellence.
Planned Recommendations from IASLC SSAC
The IASLC SSAC hosted the second CT Screening before 
the World Conference on lung cancer in Sydney 26-27 October 
2013, where all of these issues were considered fully and recom-
mendations will be provided for the international membership.
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